Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16794693 | 0.89 | MAPT (0.42) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL31245703 | 0.83 | MAPT (0.40) | MEN1KMT2AMAPTSMN1; SMN2POLB | |
| SCHEMBL22252343 | 0.81 | KMT2A (0.40) | MEN1KMT2AATMMAPTSMN1; SMN2 | |
| SCHEMBL16794676 | 0.79 | PDE1B (0.40) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL22252351 | 0.78 | CDC7 (0.44) | MEN1KMT2AATMMAPTSMN1; SMN2 | |
| SCHEMBL22252315 | 0.77 | TYK2 (0.44) | MEN1KMT2AATMMAPTSMN1; SMN2 | |
| SCHEMBL16794646 | 0.77 | MAPT (0.40) | MEN1KMT2AMAPTSMN1; SMN2POLB | |
| SCHEMBL18161034 | 0.77 | PDE1B (0.41) | MEN1KMT2ASMN1; SMN2ALDH1A1NR3C1 | |
| SCHEMBL22252388 | 0.77 | LMNA (0.36) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL1202068 | 0.77 | LMNA (0.44) | MEN1KMT2AMAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078125-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-03-19 | — | — | US | disclosed |
| US-12338242-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-24 | — | — | US | disclosed |
| US-20220073528-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-03-10 | — | — | US | disclosed |
| EP-3914357-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| US-11174264-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174264-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2020154474-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020154474-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20200231594-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
| US-20200231594-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174264-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | MEN1 2491/4885KMT2A 206/4885ATM 759/4885 |
| US-20220073528-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MEN1 2491/4885KMT2A 206/4885ATM 759/4885 |
| US-20260078125-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK3 | MEN1 4119/4885KMT2A 222/4885ATM 1016/4885 |
| US-20200231594-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | MEN1 2491/4885KMT2A 206/4885ATM 759/4885 |
| US-12338242-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | MEN1 2491/4885KMT2A 206/4885ATM 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.